SCHEMBL360401

SCHEMBL360401

CCC(CC)N1N=C(CN(C)C(=O)O)CC1=O

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SHMT2 P34897 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10080299 0.82 HTR2C (0.33)
SCHEMBL360011 0.80 L3MBTL1 (0.35) GAATDP1
SCHEMBL360170 0.79 L3MBTL1 (0.33)
SCHEMBL361217 0.78 L3MBTL1 (0.35) GAATDP1
SCHEMBL359878 0.76 ALDH1A1 (0.32) GAA
SCHEMBL359796 0.73 LMNA (0.34) GAAHPGD
SCHEMBL359437 0.72 ALDH1A1 (0.52) GAASHMT2
SCHEMBL359186 0.71 ALDH1A1 (0.51) GAA
SCHEMBL360468 0.69 KMT2A (0.38)
SCHEMBL360189 0.69 NPC1 (0.32) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312688-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-04-26 US disclosed
US-20200308119-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2020-10-01 US disclosed
US-10723703-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-07-28 US disclosed
US-20190084938-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2019-03-21 US disclosed
US-10183913-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-01-22 US disclosed
US-10087146-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-10-02 US disclosed
US-20180273489-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2018-09-27 US disclosed
US-20170217902-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2017-08-03 US disclosed
US-9663472-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-05-30 US disclosed
EP-2594559-B1 PYRAZOLE COMPOUND SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2016-02-24 EP disclosed
US-20140315971-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2014-10-23 US disclosed
US-8809383-B2 Pyrazole compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-08-19 US disclosed
US-20140031406-A1 PYRAZOLE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-01-30 US disclosed
US-8569353-B2 Pyrazole compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-10-29 US disclosed
EP-2594559-A1 PYRAZOLE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130116296-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2013-05-09 US disclosed
CN-103097357-A Pyrazole compound DAINIPPON SUMITOMO PHARMA CO 2013-05-08 CN disclosed
WO-2012008528-A1 PYRAZOLE COMPOUND 大日本住友製薬株式会社 (JP) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315971-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-10183913-B2 Pyrazole compound HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-20170217902-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-11312688-B2 Pyrazole compound HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-20130116296-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-20200308119-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-10723703-B2 Pyrazole compound HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-20180273489-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-20190084938-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-10087146-B2 Pyrazole compound HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885
US-20140031406-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A GAA 4858/4885TDP1 4230/4885SHMT2 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.